Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7021 to 7035 of 7690 results

  1. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued [GID-TA10803]

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued [GID-TA10380]

    Technology appraisal guidance
    Discontinued

  3. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued [GID-TA11151]

    Technology appraisal guidance
    Discontinued

  4. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued [GID-TAG378]

    Technology appraisal guidance
    Discontinued

  5. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued [GID-TA11171]

    Technology appraisal guidance
    Discontinued

  6. Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]

    In development [GID-TA11107] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Preterm labour and birth - predicting preterm birth

    Discontinued [GID-NG10384]

    NICE guideline
    Discontinued

  8. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued [GID-TA10365]

    Technology appraisal guidance
    Discontinued

  9. Preterm labour and birth - timing of cord clamping

    Discontinued [GID-NG10396]

    NICE guideline
    Discontinued

  10. Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

    Discontinued [GID-TA10934]

    Technology appraisal guidance
    Discontinued

  11. Intrapartum care for healthy women and babies - angle of episiotomy

    Discontinued [GID-NG10394]

    NICE guideline
    Discontinued

  12. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

    In development [GID-TA10726] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued [GID-HST10019]

    Highly specialised technologies guidance
    Discontinued

  14. Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

    Discontinued [GID-TA10707]

    Technology appraisal guidance
    Discontinued

  15. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued [GID-TA10663]

    Technology appraisal guidance
    Discontinued